Nippon Chemiphar’s Generics Business Continues To Recover
As Japanese Company Sees 2.4% Growth In Generics Segment
Nippon Chemiphar’s generics business continues to recover after two good quarters back-to-back. The Japanese company took time to stabilize after setbacks due to the adverse effect of National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic.
